Board of Directors

On July 16, 2025, the Board of Directors of the Company appointed John Duke to serve as President and Chief Executive Officer effective July 28, 2025. In this role, Mr. Duke will serve as the Company’s principal executive officer. Mr. Duke has served as a member of the Board since June 2025. From January 2024 until immediately prior to becoming Chief Executive Officer of the Company, Mr. Duke was Chief Executive Officer of Plastic Molding Technology, a plastics manufacturing company providing broad capabilities, including injection molding and thermoforming, coupled with technical expertise. From February 2021 until April 2023, Mr. Duke served as Chief Business Officer for Lyten, an Advanced Materials company that transforms greenhouse gases into Lyten 3D Graphene™ and developing innovative products across multiple industries. Prior to Lyten, Mr. Duke served in multiple positions at Corning Incorporated, one of the world's leading innovators in materials science, including Corporate Vice President, Corporate Officer, VP & GM - Glass Microsystems from April 2017 to February 2021, Vice President Sales and Marketing, Gorilla Glass from April 2016 to April 2017 and Vice President, Business Operations, Corning Life Sciences from October 2012 to March 2016. Mr. Duke holds a BS in Materials Science from University of Utah and an MBA from Harvard Business School.

Katherine Eade has been a member of the Company’s Board of Directors since October 2017. She serves as Lead Independent Director, Chair of the Nominating and Governance Committee and a member of the Audit and Compensation Committees.

Ms. Eade currently serves as Chief Legal Officer of Kyria Therapeutics, Inc. Ms. Eade previously served as General Counsel of Checkmate Pharmaceuticals, where among other things, she helped lead the sale of the company to Regeneron Pharmaceuticals at a 336% premium. She has more than 20 years of experience advising public companies on M&A, corporate governance and capital markets, as well as over ten years in leadership roles in the life sciences industry. Ms. Eade began her legal career as an attorney at Cleary Gottlieb, a leading international law firm, and served as a law clerk for Judge Morton I. Greenberg of the U.S. Court of Appeals for the Third Circuit.

Ms. Eade earned a J.D., cum laude, from Harvard Law School and a B.A. in Government, summa cum laude, from Cornell University. 

Robert Gagnon serves as chair of the Audit Committee and chair of the Compensation Committee.

Mr. Gagnon has more than 20 years of experience leading global finance operations in the life sciences industry and is an experienced public company board member with deep knowledge of Harvard Bioscience’s business, having served as the CFO of Harvard Bioscience from 2013-2018. He currently serves on the boards of Verastem Oncology, Bone Biologics and Purple Biotech.

Mr. Gagnon worked in a variety of senior positions at Deloitte & Touche, LLP, and PricewaterhouseCoopers, LLP. He holds an M.B.A. from the MIT Sloan School of Management and a bachelor of arts degree in accounting from Bentley College.

Seth Benson serves as a member of the Board of Directors and a member of the Audit Committee.

Mr. Benson has more than 20 years of leadership experience in finance, technology and operations, which includes significant time spent in life science tools. He is currently the CFO of Nuclera Ltd and previously served as the CFO of Vizgen, Inc. and VP, Strategic Finance & Investor Relations of Akoya Biosciences.

Mr. Benson holds a Bachelor of Science in Biology from Duke University and an MBA from Northwestern University's Kellogg School of Management.

Stepehen DeNelsky serves as a member of the Board of Directors and a member of the Nominating and Governance Committee.

Mr. DeNelsky has more than 30 years of leadership experience in the research, analysis, and valuation of public and private equities in the healthcare industry. He currently serves as a Managing Director at Oaktree Capital Management and was previously a Managing Director at Marathon Asset Management and President at Life Sciences Alternative Funding. Mr. DeNelsky also brings strong board experience and currently serves on the board of Visioncare Inc and previously served on the boards of Integrated Diagnostics and AMICAS, Inc.

Mr. DeNelsky received a B.A. in Economics from the American University and an M.B.A. from the University of Maryland.

William A. Snider serves as a member of the Board of Directors and a member of the Compensation Committee.

Mr. Snider, age 56, leads BroadOak’s growth capital investing activities and has worked at BroadOak since 2006. Mr. Snider has more than 30 years of institutional investment experience. Prior to BroadOak, he was a general partner and co-founder of Emerging Technology Partners, LLC (“ETP”), a life science focused venture capital firm. Prior to ETP, he was a vice president and portfolio manager at T. Rowe Price. Mr. Snider has been a director of many life sciences research tools companies and is actively involved in the investment community.

Mr. Snider holds the Chartered Financial Analyst accreditation, and a B.S.E. in Finance, as well as an M.B.A. from the Wharton School at the University of Pennsylvania.